Document is current

Article History

Received: 27 November 2024

Accepted: 6 March 2026

First Online: 23 March 2026

Declarations

:

: GHJK holds Patent UC-2013-078-2-LA-EP and has received consulting fees from Voiant and a research grant fund from Boehringer Ingelheim. FAW and CSC are employees of Avalyn Pharma Inc. and hold stock options. DN, HB, and HML are employees of Avalyn Pharma Inc. JGG reports receiving support for his written contributions to the present manuscript from Avalyn Pharma Inc., consulting fees and support for travel to meetings from Boehringer Ingelheim (education advisory board), and consulting fees from Zura. He is also a named inventor on a UCLA-owned patent (UC Patent UC-20132-078-2-LA-US, 2015) and holds stock/stock options in MedQIA.

: Local Ethics Committees/Institutional Review Boards approved the protocol for each site, and all patients provided written informed consent before enrolment. A table presenting Ethics Committees/Institutional Review Boards and approval IDs/numbers is provided in Supplemental Table 1.

: Not applicable.

: GHJK holds Patent UC-2013-078-2-LA-EP and has received consulting fees from Voiant and a research grant fund from Boehringer Ingelheim. FAW and CSC are employees of Avalyn Pharma Inc. and hold stock options. DN, HB, and HML are employees of Avalyn Pharma Inc. JGG reports receiving support for his written contributions to the present manuscript from Avalyn Pharma Inc., consulting fees and support for travel to meetings from Boehringer Ingelheim (education advisory board), and consulting fees from Zura. He is also a named inventor on a UCLA-owned patent (UC Patent UC-20132-078-2-LA-US, 2015) and holds stock/stock options in MedQIA.